Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash from Operations (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Cash from Operations data on record, last reported at 18131000.0 in Q4 2023.

  • For Q4 2023, Cash from Operations rose 27.43% year-over-year to 18131000.0; the TTM value through Dec 2023 reached 134275000.0, down 6.01%, while the annual FY2025 figure was 175750000.0, 20.95% down from the prior year.
  • Cash from Operations reached 18131000.0 in Q4 2023 per CGEM's latest filing, up from 34141000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1515000.0 in Q1 2021 and bottomed at 54353000.0 in Q3 2022.
  • Average Cash from Operations over 4 years is 20884000.0, with a median of 17163500.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: surged 69.79% in 2021, then plummeted 1346.07% in 2022.
  • A 4-year view of Cash from Operations shows it stood at 9436000.0 in 2020, then plummeted by 60.78% to 15171000.0 in 2021, then tumbled by 64.68% to 24983000.0 in 2022, then grew by 27.43% to 18131000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 18131000.0 in Q4 2023, 34141000.0 in Q3 2023, and 31006000.0 in Q2 2023.